Table 4 Treatments during hospital stay and clinical outcomes of the study patients
From: Clinical outcomes of COVID-19 in Wuhan, China: a large cohort study
|  | Not severe patients at admission (n = 1102) | Non-progressors (n = 841) | Progressors (n = 261) | p value | Severe patients (n = 349) | Survivor (n = 192) | Non-survivor (n = 157) | p value |
|---|---|---|---|---|---|---|---|---|
Treatments, n (%) | ||||||||
 Antibiotic | 905 (87.1) | 690 (84.9) | 215 (95.1) | < 0.0001 | 287 (95.4) | 169 (97.1) | 118 (92.9) | 0.0865 |
 Antifungal | 44 (4.2) | 22 (2.7) | 22 (9.7) | < 0.0001 | 28 (9.3) | 13 (7.5) | 15 (11.8) | 0.2005 |
 Antiviral | 654 (63.0) | 501 (61.6) | 153 (67.7) | 0.0943 | 180 (59.8) | 125 (71.8) | 55 (43.3) | < 0.0001 |
 Glucocorticoids | 251 (24.2) | 144 (17.7) | 107 (47.4) | < 0.0001 | 145 (48.2) | 69 (39.7) | 76 (59.8) | 0.0005 |
 Oxygen therapy, n (%) |  |  |  | < 0.0001 |  |  |  | < 0.0001 |
  None | 203 (18.4) | 201 (23.9) | 2 (0.8) |  | 2 (0.6) | 2 (1.0) | 0 |  |
  Nasal cannula | 792 (71.9) | 634 (75.4) | 158 (60.5) |  | 158 (45.3) | 142 (74.0) | 16 (10.2) |  |
  Mask oxygen | 17 (1.5) | 4 (0.5) | 13 (5.0) |  | 23 (6.6) | 16 (8.3) | 7 (4.5) |  |
  High-flow nasal cannula | 25 (2.3) | 1 (0.1) | 24 (9.2) |  | 59 (16.9) | 23 (12.0) | 36 (22.9) |  |
  Non-invasive mechanical ventilation | 34 (3.1) | 0 (0.0) | 34 (13.0) |  | 62 (17.8) | 4 (2.1) | 58 (36.9) |  |
  Invasive mechanical ventilation | 28 (2.5) | 1 (0.1) | 27 (10.3) |  | 41 (11.8) | 5 (2.6) | 36 (22.9) |  |
  ECMO | 3 (0.3) | 0 (0.0) | 3 (1.2) |  | 4 (1.2) | 0 (0.0) | 4 (2.6) |  |
Outcomes | ||||||||
 Duration of MV (IQR), days | 4 (2.0, 8.0) | 0 | 4 (2.0, 8.0) |  | 5 (2.0, 8.0) | 6 (5.0, 9.0) | 4 (2.0, 8.0) | 0.1563 |
 Duration of ICU stay (IQR), days | 0 | 0 | 6 (3.0, 10.0) |  | 6 (3.0, 10.5) | 7 (4.0, 11.0) | 5 (2.0, 9.0) | 0.0522 |
 Duration of in-hospital stay (IQR), days | 11 (8.00, 15.00) | 11 (8.0, 14.0) | 12 (8.0, 16.0) | 0.0021 | 11 (7, 16) | 14 (10.0, 18.0) | 8 (4.0, 12.0) | < 0.0001 |
 In-hospital mortality, n (%) | 91 (8.26) | 0 (0.0) | 91 (34.9) | < 0.0001 | 157 (45.0) | 0 (0.0) | 157 (100.0) | < 0.0001 |